Literature DB >> 22191428

Biophysical characterization of a riboflavin-conjugated dendrimer platform for targeted drug delivery.

Amanda B Witte1, Christine M Timmer, Jeremy J Gam, Seok Ki Choi, Mark M Banaszak Holl, Bradford G Orr, James R Baker, Kumar Sinniah.   

Abstract

The present study describes the biophysical characterization of generation-five poly(amidoamine) (PAMAM) dendrimers conjugated with riboflavin (RF) as a cancer-targeting platform. Two new series of dendrimers were designed, each presenting the riboflavin ligand attached at a different site (isoalloxazine at N-3 and d-ribose at N-10) and at varying ligand valency. Isothermal titration calorimetry (ITC) and differential scanning calorimetry (DSC) were used to determine the binding activity for riboflavin binding protein (RfBP) in a cell-free solution. The ITC data shows dendrimer conjugates have K(D) values of ≥ 465 nM on a riboflavin basis, an affinity ~93-fold lower than that of free riboflavin. The N-3 series showed greater binding affinity in comparison with the N-10 series. Notably, the affinity is inversely correlated with ligand valency. These findings are also corroborated by DSC, where greater protein-conjugate stability is achieved with the N-3 series and at lower ligand valency.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22191428      PMCID: PMC3279152          DOI: 10.1021/bm201566g

Source DB:  PubMed          Journal:  Biomacromolecules        ISSN: 1525-7797            Impact factor:   6.988


  44 in total

1.  Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy.

Authors:  Anil K Patri; Andrzej Myc; James Beals; Thommey P Thomas; Neil H Bander; James R Baker
Journal:  Bioconjug Chem       Date:  2004 Nov-Dec       Impact factor: 4.774

2.  Light-controlled release of caged doxorubicin from folate receptor-targeting PAMAM dendrimer nanoconjugate.

Authors:  Seok Ki Choi; Thommey Thomas; Ming-Hsin Li; Alina Kotlyar; Ankur Desai; James R Baker
Journal:  Chem Commun (Camb)       Date:  2010-02-06       Impact factor: 6.222

3.  Binding thermodynamics as a tool to investigate the mechanisms of drug-receptor interactions: thermodynamics of cytoplasmic steroid/nuclear receptors in comparison with membrane receptors.

Authors:  Paola Gilli; Gastone Gilli; Pier Andrea Borea; Katia Varani; Angelo Scatturin; Alessandro Dalpiaz
Journal:  J Med Chem       Date:  2005-03-24       Impact factor: 7.446

4.  Rational design of RGD-albumin conjugates for targeted delivery of the VEGF-R kinase inhibitor PTK787 to angiogenic endothelium.

Authors:  Kai Temming; Marie Lacombe; Roel Q J Schaapveld; László Orfi; Gyorgy Kéri; Klaas Poelstra; Grietje Molema; Robbert J Kok
Journal:  ChemMedChem       Date:  2006-11       Impact factor: 3.466

Review 5.  Syntheses and some applications of chemically defined multivalent glycoconjugates.

Authors:  R Roy
Journal:  Curr Opin Struct Biol       Date:  1996-10       Impact factor: 6.809

6.  Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer.

Authors:  Jolanta F Kukowska-Latallo; Kimberly A Candido; Zhengyi Cao; Shraddha S Nigavekar; Istvan J Majoros; Thommey P Thomas; Lajos P Balogh; Mohamed K Khan; James R Baker
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

7.  Evaluation of riboflavin binding protein domain interaction using differential scanning calorimetry.

Authors:  Marcin Wasylewski
Journal:  Biochim Biophys Acta       Date:  2004-11-01

8.  Riboflavin-mediated delivery of a macromolecule into cultured human cells.

Authors:  S R Holladay; Z Yang; M D Kennedy; C P Leamon; R J Lee; M Jayamani; T Mason; P S Low
Journal:  Biochim Biophys Acta       Date:  1999-01-04

9.  Biosensor-based determination of riboflavin in milk samples.

Authors:  Isabelle Caelen; Andras Kalman; Lennart Wahlström
Journal:  Anal Chem       Date:  2004-01-01       Impact factor: 6.986

10.  Biochemical characterization of riboflavin carrier protein (RCP) in prostate cancer.

Authors:  Tanya Johnson; Allal Ouhtit; Rajiv Gaur; Augusta Fernando; Paul Schwarzenberger; Joseph Su; Mohamed F Ismail; Hassan I El-Sayyad; Anjali Karande; Zakaria Abd Elmageed; Prakash Rao; Madhwa Raj
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more
  5 in total

1.  Design and in vitro validation of multivalent dendrimer methotrexates as a folate-targeting anticancer therapeutic.

Authors:  Thommey P Thomas; Melvin Joice; Madhuresh Sumit; Justin E Silpe; Alina Kotlyar; Sophia Bharathi; Jolanta Kukowska-Latallo; James R Baker; Seok Ki Choi
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 2.  Mechanisms and implications of dual-acting methotrexate in folate-targeted nanotherapeutic delivery.

Authors:  Pamela T Wong; Seok Ki Choi
Journal:  Int J Mol Sci       Date:  2015-01-13       Impact factor: 5.923

Review 3.  Riboflavin-Targeted Drug Delivery.

Authors:  Milita Darguzyte; Natascha Drude; Twan Lammers; Fabian Kiessling
Journal:  Cancers (Basel)       Date:  2020-01-27       Impact factor: 6.639

4.  Riboflavin-citrate conjugate multicore SPIONs with enhanced magnetic responses and cellular uptake in breast cancer cells.

Authors:  Wid Mekseriwattana; Pablo Guardia; Beatriz Torres Herrero; Jesus M de la Fuente; Chutima Kuhakarn; Anna Roig; Kanlaya Prapainop Katewongsa
Journal:  Nanoscale Adv       Date:  2022-03-02

5.  Atomic force microscopy probing of receptor-nanoparticle interactions for riboflavin receptor targeted gold-dendrimer nanocomposites.

Authors:  Amanda B Witte; Abigail N Leistra; Pamela T Wong; Sophia Bharathi; Kevin Refior; Phillip Smith; Ola Kaso; Kumar Sinniah; Seok Ki Choi
Journal:  J Phys Chem B       Date:  2014-03-07       Impact factor: 2.991

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.